Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Japan, February 3, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; president and CEO: Masafumi Nogimori) announced today that it will implement changes to its global development...
Read more about Astellas Announces Global Development Organizational Changes
Tokyo, Japan, January 27, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that it has submitted a proposal to the Board of Directors of CV Therapeutics, Inc. (Nasdaq: CVTX) to...
Read more about ASTELLAS PROPOSES TO ACQUIRE CV THERAPEUTICS FOR $16 PER SHARE IN CASH
Japan, January 21, 2009 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc. (“Astellas”; headquarters:...
Read more about Approval for the Osteoprosis Treatment, RECALBON® Tablets / Bonoteo® Tablets
December 24, 2008- Tokyo - Ajinomoto Co., Inc. (Headquarters: Tokyo, President & CEO: Norio Yamaguchi) and Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori) announced...
Japan, December 15, 2008 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that it completed acquisition of...
Read more about Notice of Completion of Acquisition of Treasury Stock
Japan, November 20, 2008 - Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, “Astellas”) announced today that an injectable antibiotic, in-licensed from...
Read more about Astellas Announces the Outcome of FDA's Advisory Committee in the US for Telavancin
Japan, November 18, 2008 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it has established its subsidiary, Astellas Pharma India...
Read more about Astellas Establishes a Marketing Subsidiary in India
Japan, November 5, 2008 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) announced that at the meeting of the Board of...
Read more about Astellas Announces Acquisition of Treasury Stock
Japan, October 27, 2008 - Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, “Astellas”) today announced that its immunosuppressant Graceptor® Capsules 0.5mg,...
Read more about Astellas Launches the Immunosuppressant Graceptor®in Japan
Japan, October 24, 2008 - Astellas Pharma Inc. (Astellas) announced today it has withdrawn a European marketing authorisation application (MAA) for telavancin, a bactericidal, once-daily...
Japan, October 6, 2008 - Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, “Astellas”) today announced that its serotonin 5-HT3 receptor antagonist Irribow®...
Read more about Astellas Launches Irribow® for the Treatment of Irritable Bowel Syndrome
Astellas Pharma Inc. (“Astellas”; President and CEO: Masafumi Nogimori) announced today that it has decided to dissolve its European subsidiary, Fujisawa Ireland Ltd. (headquarters: Kerry,...
Read more about Dissolution of the European Subsidiary Fujisawa Ireland Ltd.
Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo; President and CEO: Masafumi Nogimori) has completed the new buildings in its Tsukuba Research Center (Miyukigaoka) this September and...
Read more about Astellas Completes the New Buildings in its Tsukuba
Follow us
